156 related articles for article (PubMed ID: 32681522)
1. A retrospective analysis comparing persistence and adherence to treatment with free- vs fixed-dose combination of an alpha blocker and an antimuscarinic agent in men with LUTS in Spain.
Landeira M; Mora Blázquez AM; Martins de Almeida R; Covernton PJO; Medina-Polo J; Alcántara Montero A
Int J Clin Pract; 2020 Nov; 74(11):e13616. PubMed ID: 32681522
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.
Drake MJ; Bowditch S; Arbe E; Hakimi Z; Guelfucci F; Amri I; Nazir J
BMC Urol; 2017 May; 17(1):36. PubMed ID: 28532455
[TBL] [Abstract][Full Text] [Related]
3. Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
.
Eisen C; Lulic Z; Palacios-Moreno JM; Adalig B; Hennig M; Cortes V; Gilg F; Kostev K
Int J Clin Pharmacol Ther; 2020 Jan; 58(1):37-49. PubMed ID: 31670653
[TBL] [Abstract][Full Text] [Related]
4. Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
Barkin J; Diles D; Franks B; Berner T
Can J Urol; 2015 Aug; 22(4):7914-23. PubMed ID: 26267031
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs.
Lokhandwala T; Smith N; Sternhufvud C; Sörstadius E; Lee WC; Mukherjee J
J Med Econ; 2016; 19(3):203-12. PubMed ID: 26473990
[TBL] [Abstract][Full Text] [Related]
6. The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study.
Ali M; Landeira M; Covernton PJO; Choudhury N; Jaggi A; Fatoye F; van Maanen R
BMC Urol; 2021 Sep; 21(1):119. PubMed ID: 34474675
[TBL] [Abstract][Full Text] [Related]
7. Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database.
Wagg AS; Foley S; Peters J; Nazir J; Kool-Houweling L; Scrine L
Int J Clin Pract; 2017 Oct; 71(10):. PubMed ID: 28906080
[TBL] [Abstract][Full Text] [Related]
8. Does tablet formulation alone improve adherence and persistence: a comparison of ezetimibe fixed dose combination versus ezetimibe separate pill combination?
Bartlett LE; Pratt N; Roughead EE
Br J Clin Pharmacol; 2017 Jan; 83(1):202-210. PubMed ID: 27517705
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
[TBL] [Abstract][Full Text] [Related]
10. Adherence and medication utilisation patterns of fixed-dose and free combination of angiotensin receptor blocker/thiazide diuretics among newly diagnosed hypertensive patients: a population-based cohort study.
Hsu CI; Hsiao FY; Wu FL; Shen LJ
Int J Clin Pract; 2015 Jul; 69(7):729-37. PubMed ID: 25395349
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
Nazir J; Hakimi Z; Guelfucci F; Khemiri A; Fatoye F; Blázquez AMM; González MH
BMC Urol; 2018 Sep; 18(1):76. PubMed ID: 30180826
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
[TBL] [Abstract][Full Text] [Related]
13. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
Hakimi Z; Johnson M; Nazir J; Blak B; Odeyemi IA
Curr Med Res Opin; 2015 Jan; 31(1):43-50. PubMed ID: 25333647
[TBL] [Abstract][Full Text] [Related]
14. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis.
Han S; Iglay K; Davies MJ; Zhang Q; Radican L
Curr Med Res Opin; 2012 Jun; 28(6):969-77. PubMed ID: 22494018
[TBL] [Abstract][Full Text] [Related]
15. Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
Cindolo L; Pirozzi L; Sountoulides P; Fanizza C; Romero M; Castellan P; Antonelli A; Simeone C; Tubaro A; de Nunzio C; Schips L
BMC Urol; 2015 Sep; 15():96. PubMed ID: 26391357
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.
van Kerrebroeck P; Chapple C; Drogendijk T; Klaver M; Sokol R; Speakman M; Traudtner K; Drake MJ;
Eur Urol; 2013 Dec; 64(6):1003-12. PubMed ID: 23932438
[TBL] [Abstract][Full Text] [Related]
17. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy.
Patel BV; Remigio-Baker RA; Thiebaud P; Preblick R; Plauschinat C
BMC Fam Pract; 2008 Nov; 9():61. PubMed ID: 18990240
[TBL] [Abstract][Full Text] [Related]
18. Early symptom improvement and discontinuation of 5-α-reductase inhibitor (5ARI) therapy in patients with benign prostatic hyperplasia (BPH).
Kruep EJ; Phillips E; Hogue S; Eaddy M
Ann Pharmacother; 2014 Mar; 48(3):343-8. PubMed ID: 24311727
[TBL] [Abstract][Full Text] [Related]
19. Medication Adherence and Clinical Outcome of Fixed-Dose Combination vs. Free Combination of Angiotensin Receptor Blocker and Statin.
Choi JM; Lee SH; Jang YJ; Kang M; Choi JH
Circ J; 2021 Apr; 85(5):595-603. PubMed ID: 33790135
[TBL] [Abstract][Full Text] [Related]
20. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
